Advertisement
Screener

ADC Therapeutics SA (ADCT) Increase Decrease In Deferred Tax Liability Asset

2.8 / 5 stars · 68/120 Roast Me

ADC Therapeutics SA Increase Decrease In Deferred Tax Liability Asset

ADC Therapeutics SA (ADCT) reported Increase Decrease In Deferred Tax Liability Asset of $8.64 million for the 9-month period ending 2023-09-30, per its 6-K filed 2023-11-07.

Discontinued › Notes › Income Taxes

ifrs-full:IncreaseDecreaseInDeferredTaxLiabilityAsset · last filed 2023-11-07

  • ADC Therapeutics SA increase decrease in deferred tax liability asset for the quarter ending 2023-09-30 was $578.00K.
  • ADC Therapeutics SA increase decrease in deferred tax liability asset for the quarter ending 2023-06-30 was $7.22M, a 74.53% increase year-over-year.
  • ADC Therapeutics SA increase decrease in deferred tax liability asset for the quarter ending 2023-03-31 was $848.00K, a 78.01% decline year-over-year.
  • ADC Therapeutics SA increase decrease in deferred tax liability asset for the quarter ending 2022-12-31 was -$6.84M, a 126.27% decline year-over-year.
Period endIncrease Decrease In Deferred Tax Liability Asset 3 monthIncrease Decrease In Deferred Tax Liability Asset 6 monthIncrease Decrease In Deferred Tax Liability Asset 9 monthIncrease Decrease In Deferred Tax Liability Asset 12 monthIncrease Decrease In Deferred Tax Liability Asset 12 month as first filed
2023-09-30$578.00K
derived: 6-K 9 month − 6-K 6 month · filed 2023-11-07
$7.79M
derived: sum of 2 quarters · filed 2023-11-07
$8.64M
6-K · filed 2023-11-07
$1.80M
derived: sum of 4 quarters · filed 2023-11-07
2023-06-30$7.22M
derived: 6-K 6 month − 6-K 3 month · filed 2023-08-08
$8.06M
6-K · filed 2023-08-08
$1.22M
derived: sum of 3 quarters · filed 2023-08-08
$782.00K
derived: sum of 4 quarters · filed 2023-11-07
2023-03-31$848.00K
6-K · filed 2023-05-09
-$5.99M
derived: sum of 2 quarters · filed 2023-05-09
-$6.43M
derived: sum of 3 quarters · filed 2023-11-07
-$2.30M
derived: sum of 4 quarters · filed 2023-11-07
2022-12-31-$6.84M
derived: 20-F 12 month − 6-K 9 month · filed 2023-03-15
-$7.28M
derived: sum of 2 quarters · filed 2023-11-07
-$3.15M
derived: sum of 3 quarters · filed 2023-11-07
$708.00K
20-F · filed 2023-03-15
2022-09-30-$441.00K
derived: 6-K 9 month − 6-K 6 month · filed 2023-11-07
$3.69M
derived: sum of 2 quarters · filed 2023-11-07
$7.55M
6-K · filed 2023-11-07
$33.60M
derived: sum of 4 quarters · filed 2023-11-07
2022-06-30$4.13M
derived: 6-K 6 month − 6-K 3 month · filed 2023-08-08
$7.99M
6-K · filed 2023-08-08
$34.04M
derived: sum of 3 quarters · filed 2023-08-08
$34.04M
derived: sum of 4 quarters · filed 2023-08-08
2022-03-31$3.86M
6-K · filed 2023-05-09
$29.91M
derived: sum of 2 quarters · filed 2023-05-09
$29.91M
derived: sum of 3 quarters · filed 2023-05-09
$29.91M
derived: sum of 4 quarters · filed 2023-05-09
2021-12-31$26.05M
derived: 20-F 12 month − 6-K 9 month · filed 2023-03-15
$26.05M
derived: sum of 2 quarters · filed 2023-03-15
$26.05M
derived: sum of 3 quarters · filed 2023-03-15
$26.05M
20-F · filed 2023-03-15
$2.78M
20-F · filed 2022-03-17
2021-09-30$0.00
derived: 6-K 9 month − 6-K 6 month · filed 2022-11-08
$0.00
derived: sum of 2 quarters · filed 2022-11-08
$0.00
6-K · filed 2022-11-08
2021-06-30$0.00
derived: 6-K 6 month − 6-K 3 month · filed 2022-08-09
$0.00
6-K · filed 2022-08-09
2021-03-31$0.00
6-K · filed 2022-05-09
2020-12-31$0.00
20-F · filed 2023-03-15

Similar stocks

Stock NameCountryMarket CapPE Ratio
LIFECORE BIOMEDICAL, INC. DE (LFCR)United States$0.163B-8.50
Minerva Neurosciences, Inc. (NERV)United States$0.165B-0.66
Tonix Pharmaceuticals Holding Corp. (TNXP)United States$0.166B-1.34
Annexon, Inc. (ANNX)United States$0.147B-4.22
Organogenesis Holdings Inc. (ORGO)United States$0.182B-3.70
Corbus Pharmaceuticals Holdings, Inc. (CRBP)United States$0.144B-1.72
AN2 Therapeutics, Inc. (ANTX)United States$0.185B-4.84
SPRUCE BIOSCIENCES, INC. (SPRB)United States$0.142B-2.89
Korro Bio, Inc. (KRRO)United States$0.141B-1.81
PepGen Inc. (PEPG)United States$0.186B-1.73